OKYO Pharma Limited (NASDAQ:OKYO) has a beta value of -0.25 and has seen 0.45 million shares traded in the last trading session. The company, currently valued at $42.34M, closed the last trade at $1.25 per share which meant it gained $0.08 on the day or 6.84% during that session. The OKYO stock price is -56.0% off its 52-week high price of $1.95 and 35.2% above the 52-week low of $0.81. If we look at the company’s 10-day average daily trading volume, we find that it stood at 31490.0 shares traded. The 3-month trading volume is 59.72K shares.
The consensus among analysts is that OKYO Pharma Limited (OKYO) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.
OKYO Pharma Limited (NASDAQ:OKYO) trade information
Sporting 6.84% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the OKYO stock price touched $1.25 or saw a rise of 5.3%. Year-to-date, OKYO Pharma Limited shares have moved 8.65%, while the 5-day performance has seen it change 8.65%. Over the past 30 days, the shares of OKYO Pharma Limited (NASDAQ:OKYO) have changed 20.13%. Short interest in the company has seen 0.22 million shares shorted with days to cover at 6.58.
OKYO Pharma Limited (OKYO) estimates and forecasts
Figures show that OKYO Pharma Limited shares have outperformed across the wider relevant industry. The company’s shares have gained 6.79% over the past 6 months, with this year growth rate of 29.82%, compared to 17.00% for the industry. Revenue growth from the last financial year stood is estimated to be 0.00%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -126.59% over the past 5 years.
OKYO Dividends
OKYO Pharma Limited is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
